## Additional document 1 Overview of comparative peer-reviewed publications on elements of pricing and reimbursement since 2010

(this is an indicative overview of publications focusing on institutional practices related to the process of reimbursement and/or pricing, and examining a minimum of three countries neluding at least one European country) Full references are provided on page 2.

					European Countries																																	
	Associated & Candidate														ž.		Addit	ional :	OECT	CD Countries																		
Authors	Year	Focus	Number of countries	Data collection	AT BI	E BG	CY	CZ E	DE DI	EE.	EL	ES	FI	FR G			ΙE	IT	LT I	LU L	.V M	T NI	. PL	РТ	RO	SE	SI S	SK C			) TR	AU	CA			R MX		
Barnieh et al. (1)	2014	procedural elements, outpatient perscription drugs	34	2011										E S																								
Allen et al. (2)	2013	construction of archetypes for the role of national HTA systems in decision-making	33	unclear										E																								
Leopold et al. (3)	2013	pricing and reimbursement challenges in personalised medicine	29	2011										Е	1																							
Riedel et al. (4)	2013	economic evaluation (type, perspective, utility values, discounting, modeling)	12	2011										Е	ł																							
Spinner et al. (5)	2013	impact of clinical evidence base on decision- making (comparators, selective decision- making, indirect comparisons etc.)	3	2011										Е	ł.																							
Cleemput et al. (6)	2012	"accountability for reasonableness" conditions (transparency, relevance, revisability, enforcement)	5	2012																																		
Franken et al. (7)	2012	objective, Implementation modalities and accountability	5	2012																																		
Kleijnen et al. (8)	2012	methodological elements in comparative effectiveness research	29	2011										E S	:																							
Leopold et al. (9)	2012	external reference pricing (basket composition, price calculation)	28	2009-2010										*	:																							
Vogler (10)	2012	generics policies (price control, price linkage, substitution, INN prescribing)	29	2011										*	:																							
Mauskopf et al. (11)	2011	submission requirements (systematic review/meta-analysis, critical appraisal etc.)	10	unclear										E S																								
Stafinski et al. (12)	2011	procedural elements in reimbursement decisions on new technologies	21	2010										*	1																							
Vogler et al. (13)	2011	pricing and reimbursement elements based on Pharmaceutical Health Information System indicators	28	2010										*																								
Drummond et al. (14)	2010	case studies focusing on price and reimbursement status differences	4	2009										E S																								
Levy et al. (15)	2010	process for inclusion in national reimbursement list (formulary)	5	2009										S																								

(Note: E = England; S = Scotland; \*no (clear) distinction within Great Britain)

- 1. Barnieh L, Clement F, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, Manns B: A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. PLoS One 2014. 9:e90434.
- 2. Allen N, Pichler F, Wang T, Patel S, Salek S: Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems. Health Policy 2013, 113:305-312.
- 3. Leopold C, Vogler S, Habl C, Mantel-Teeuwisse AK, Espin J: Personalised medicine as a challenge for public pricing and reimbursement authorities A survey among 27 European countries on the example of trastuzumab. Health Policy 2013, 113:313-322.
- 4. Riedel R, Repschlager U, Griebenow R, Breitkopf S, Schmidt S, Guhl A: International standards for health economic evaluation with a focus on the German approach. J Clin Pharm Ther 2013, 38:277-285.
- 5. Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C: Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. ClinicoEconomics and outcomes research: CEOR 2013, 5:69-85.
- 6. Cleemput I, Franken M, Koopmanschap M, le Polain M: European drug reimbursement systems' legitimacy: five-country comparison and policy tool. Int J Technol Assess Health Care 2012, 28:358-366.
- 7. Franken M, le Polain M, Cleemput I, Koopmanschap M: Similarities and differences between five European drug reimbursement systems. Int J Technol Assess Health Care 2012, 28:349-357.
- 8. Kleijnen S, George E, Goulden S, d'Andon A, Vitre P, Osinska B, Rdzany R, Thirstrup S, Corbacho B, Nagy BZ, et al: Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. Value Health 2012, 15:954-960.
- 9. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R: Differences in external price referencing in Europe: a descriptive overview. Health Policy 2012, 104:50-60.
- 10. Vogler S: The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries an overview. Generics and Biosimilars Initiative Journal 2012, 1:93-100.
- 11. Mauskopf J, Walter J, Birt J, Bowman L, Copley-Merriman C, Drummond M: Differences among formulary submission guidelines: implications for health technology assessment. Int J Technol Assess Health Care 2011, 27:261-270.
- 12. Stafinski T, Menon D, Davis C, McCabe C: Role of centralized review processes for making reimbursement decisions on new health technologies in Europe. ClinicoEconomics and Outcomes Research (Dovepress) 2011, 3:117-186.
- 13. Vogler S, Habl C, Bogut M, Voncina L: Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J 2011, 52:183-197.
- 14. Drummond M, Jönsson B, Rutten F, Stargardt T: Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. The European journal of health economics: HEPAC: health economics in prevention and care 2011, 12:263-271.
- 15. Levy AR, Mitton C, Johnston KM, Harrigan B, Briggs AH: International comparison of comparative effectiveness research in five jurisdictions: insights for the US. Pharmacoeconomics 2010, 28:813-830.